Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Inclusion Criteria:

• 18-65 years

• histologically confirmed de novo Non Hodgkin's lymphoma (except highly aggressivelymphoma such as lymphoblastic lymphoma and Burkitt lymphoma)

• plan to be given 6-8 cycles of cyclophosphamide, doxorubicin, vincristine, andprednisone (CHOP) ± Rituximab (R)

• KPS ≥70

• plan continuous PEG-rhG-CSF or rhG-CSF adiministration after at least 3 cycles oftreatment for neutropenia prophylactic treatment

• absolute neutrophil count≥1.5×109/L，platelet count ≥100× 109/L，hemoglobin≥90g/L，whileblood cell count≥3.0×109/L，without bleeding signs

• adquate liver and renal function as protocol discribed

• no serious cardiovascular disease as protocol discribed

• under good mental conditions and informed consented

• potential benefit for subjects based on investigators' decision

Exclusion Criteria:

• history of hematopoetic stem cell transplantationor organ transplantation

• uncontrollable infection

• allergic to study drugs or ingredients

• accepted any other investigational drug or participated another interventional studywithin 30 days during screening period

• other uncontrollable conditions judged by the investigator

• breast-feeding , pregnant or plan to be pregnant during study observation period